NSAID Use May Affect Axial Spondyloarthritis Diagnosis via MRI
Findings suggest that patients with suspected axial spondyloarthropathy not taking NSAIDs were more likely to have MRI proven inflammation compared with patients taking NSAIDs.
Patients with suspected axial spondyloarthropathy (AxSpA) not taking non-steroidal anti-inflammatory drugs (NSAIDs) are more likely to have MRI proven inflammation compared with those taking NSAIDs, according to study results presented at the Radiological Society of North America (RSNA) 2021 Annual Meeting.
“Undiagnosed AxSpA can have significant impact on patients’ physical and mental health but also their quality of life and livelihood,” the authors wrote. “It is possible that NSAID use at the time of scanning reduces the diagnostic yield of MRI scanning.”
The findings were presented by Prasanna Partha Sarathy, MBChB, BMedSc, of Singleton Hospital in Swansea, UK.
Early AxSpA diagnosis, which depends on HLA-B27 testing and MRI imaging, is essential. While NSAIDs can lead to improvement in MRI appearances, patients suspected of having AxSpA are often prescribed these drugs for symptomatic relief before imaging. In this study, the researchers assessed the use of MRI in patients with suspected AxSpA and the effect of NSAIDs on the diagnostic yield of MRI scanning.
The six-month, multicenter, retrospective cohort study included 74 patients referred for MRI of the spine for suspected AxSpA. At the time of MRI, the patients were asked about NSAID use. The MRI results were assessed for evidence of active inflammation.
MRI showed signs of AxSpA in 22% of the patients. Those not using NSAIDs at the time of the scan were more likely to have MRI proven inflammation (P = .017). After adjusting for age and gender, the study found that patients not taking NSAIDs were more likely to have MRI proven inflammation compared with those taking NSAIDs (OR 8.3; 95% CI, 1.9-36; P = .005). This finding was mainly driven by the no NSAID versus regular NSAID use subgroups (OR 14; 95% CI, 2.1-97; P = .006). No difference was seen between patients not taking NSAIDs and those taking NSAIDs as required, or between patients taking NSAIDs as required versus those taking regular NSAIDs.
“This study suggests suspected AxSpA patients not taking NSAIDs were more likely to have MRI proven inflammation compared to patients taking NSAIDs especially those on regular NSAIDs,” the authors wrote.
They suggested that more prospective research is needed to explore this relationship further.
For more coverage of RSNA 2021, click here.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
